Upside – $KOD +60% (pivotal Phase 3 DAYBREAK wet-AMD trial met its primary noninferiority endpoints, with most patients reaching a 24-week dosing interval) – $ARAY +39% (agrees to explore integrating Samsung NeuroLogica volumetric imaging technology with the CyberKnife platform) – $MEDS +28% (launches a GLP-1 care app offering telehealth consultations and access to branded medications) …
Read in context ›Kodiak Sciences Stock (KOD)
Track Kodiak Sciences stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
KOD
Kodiak Sciences
healthcare
At close
$99.87
▲ +5.61 (+5.95%)
Oct 9, 4:00 PM ET
After-hours
$100.27
▲ +0.40 (+0.40%)
Oct 9, 7:59 PM ET
Market Cap
$5.92B
P/E Ratio
—
1Y Return
+551.87%
EPS (TTM)
-$4.19
Read the latest TheStreet Pro articles mentioning Kodiak Sciences, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
1 articleDaily Diary Mentions
1 mentionUpside, Downside Movers in the Morning